The most serious threat to a claudicant is not the possible future need for a major amputation, but rather that the medium-term mortality is two to three times that of the general age-matched population. In patients with more severe disease in the legs, approximately 45% will have had a major amputation or be dead within a year of developing rest pain, ulcers or gangrene. These are the challenges for pharmacotherapy in peripheral arterial occlusive disease. In the short and medium term, pharmacotherapy can only have a significant effect by modifying the microcirculatory response to the low perfusion pressure caused by the arterial disease. The microcirculatory changes in the leg in severe leg ischaemia are ill understood, but theoretically a number of pharmacological effects could be beneficial. In practice, the only type of drugs widely tested clinically in severe leg ischaemia are prostacyclin and its analogues. In the last 12 years the results of properly controlled randomized trials involving patients with chronic limb ischaemia have been carried out in approximately 2000 patients in Europe. The largest number were entered into trials using the prostacyclin analogue iloprost. Some of these trials have shown a significant benefit compared to placebo in terms of major amputation or death during the 6 months following a 2-4-week course of intravenous i1oprost. The possible future indications for this type of therapy, as well as the use for prostaglandins in claudicants, is discussed.
The real problem of patients with PAOD
We often see a man pass away by degrees. and limb by limb lose the sensation of life: first the toes of the feet grow livid, next die the feet and legs. afterwards over the other limbs go creeping the cold footsteps of death.
Lucretius (96-55 Be)
Although patients with peripheral arterial occlusive disease (PAOD) usually present to their doctor with symptoms of mild claudication, limitation of pain-free walking is not their real problem. It is not even the threat of losing their leg, as no more than 2-3% of all claudicants ever come to a major amputation. Their real problem is that they are likely to die 10 years earlier than their non-claudicating friends. Several large epidemiological studies with longterm follow-up have now shown that the relative risk of all-cause mortality in a claudicant is two to three times that of the general age-matched population, even after correcting for other risk factors for death. The fact that the patient probably does not appreciate that his life expectancy is decreased may not matter, but all too often the doctors looking after him do not seem to take this into account in their management either. In many countries such patients are usually treated by vascular surgeons whose therapeutic target is only the local lesion causing the claudication.
The same limited mechanistic aim also often prevails in the management of patients with more severe PAOD, presenting with ischaemic rest pain, gangrene or ulcers. Such patients are at an even greater risk of losing their life, often shortly after losing their leg. Such patients almost invariably receive active treatment as far as their legs are concerned, usually involving reconstructive arterial surgery or occasionally a percutaneous catheter procedure. But even with the best currently available treatment 45% of these patients will have had a major amputation or be dead within a year of developing rest pain, ulcers or gangrene. I Very few, if any, of these deaths are directlyattributable to the PAOD. However, there is a very close association. There are now a number of studies, the largest being PACK (Prevention of Atherosclerotic Complications), which showed that the best predictor of all-cause mortality in patients with PAOD is the ankle/brachial pressure index which is only a measure of the arterial disease in the legs.' Whilst the obvious explanation for such an association would be that the PAOD is simply a marker for central coronary or cerebral vascular disease, there are other more intriguing possible links. For instance, the priming or activation of circulating leucocytes as they travel through the ischaemic leg. The link between inappropriate leucocyte activation and myocardial ischaemia, even arrhythmia, is now increasingly accepted.'
Critical leg ischaemia
The fundamental difference between intermittent claudicants and patients with more severe leg ischaemia is that for the vast majority of the day the former have no pathological or symptomatic disease; by contrast, patients with rest pain, gangrene or ulcers have a permanent circulatory deficiency and more or less continuous symptoms. The term chronic critical leg ischaemia (CLI) was first coined in 1982 to describe a subgroup of patients with continuous leg ischaemia who are in particular danger of losing their leg in the absence of a successful intervention. Since then the term has been redefined on several occasions on both sides of the Atlantic. For the purpose of this contribution, the term CLI will be used as an abbreviation to include all patients with proven ischaemic rest pain, gangrene or ulcer. This is a useful concept because patients with CLI have a different prognosis and require different management from patients who merely c1audicate intermittently.
At present, in most countries, patients with CLI are primarily managed by vascular surgeons, as successful revascularization is perceived to be the most urgent and effective treatment. However, as a vascular surgeon, I have to admit that the current results of attempts at revascularization are in general not as spectacular as one is led to believe by individual reports from specialized centres. For instance, the limb salvage rate for distal bypasses in individual series is frequently as high as 85%, while an audit of what actually happens to patients in a geographical area after such procedures shows that the limb salvage rate is around 40%.4 A recent, well-audited, study of 517 distal bypasses for CLI carried out in 23 European centres of supposed excellence showed that only 62% of the patients were alive without an amputation a year after their operation. Thus, clearly surgery alone is not the only answer to the management of these patients. It is also necessary to have a strategy for a more generalized systemic treatment in these patients with end-stage CLI. Such a strategy has to be based on some form of pharmacological intervention usually aimed at the microcirculation.
Microcirculation in eLi
It is the microcirculation of the skin which appears to be particularly at risk in CLI; it is probably the source of the ischaemic rest pain and is the tissue where necrosis first becomes apparent. There is a complex regulatory system adjusting the microcirculation in the skin, where under normal conditions only 5-10% of the total blood flow is nutritional. The abnormal microcirculation in CLI is partly due to the breakdown of this normal flow regulatory system often manifested by abnormal vasomotion. It is also partly due to the inappropriate activation of the microcirculatory defence mechanism. The microcirculatory defence system is designed to combat injury, in particular infection. Its most important components are the endothelial cells and the circulating platelets and white cells. Under normal resting conditions these cells are in a non-adhering passive state. It is suggested that in CLI, partly as a result of low perfusion pressure and partly the result of the atherosclerosis, these key players in the microvascular defence system become inappropriately activated. The activated leucocytes release proteolytic enzymes which attack the endothelium, plateletactivating factor, leukotrines and oxygen free radicals. The activated platelets aggregate, adhere and also release platelet-activating factor, thromboxane, plasminogen activator inhibitor and platelet derived growth factor. The balance of prothrombotic and antithrombotic factors is tilted towards Vascular Medicine 1996; 1: 155-158 the former. The damaged endothelium also releases plasminogen activator inhibitor, unmasks adhesion molecules and possibly decreases the release of prostacyclin. The situation of mutually activating and amplifying activated cells results in a vicious spiral causing local tissue damage and further disturbance of the flow regulating system by blocking the microcirculation.' The balance between the normal factors preventing abnormal activation and adhesion of the cells and the proactivating stimuli is tilted in favour of the latter in patients with CLI.
One rationale for pharmacotherapy is to prevent this inappropriate activation of the microcirculatory defence system and to normalize the microcirculatory flow regulation distal to an arterial occlusion. There are a variety of drugs of proven efficacy in cardiovascular protection which affect the system at individual points, for instance the commonly used antiplatelet agents. These have mostly been tested clinically in a relatively steady-state system. In CLI the microcirculatory vicious spiral tends to cause rapid deterioration and a more powerful, and probably multiaction, drug would seem to be more appropriate. The only type of drug so far widely tested clinically, which may have these prerequisites, are prostacyclin and its analogues.
Pharmacology of prostacyclin
Prostacyclin was discovered by Vane in 1976. It was recognized to be normally produced by endothelium and platelets. It is a powerful local vasodilator and appears to protect the endothelium against a number of damaging influences. Prostacyclin also has an effect on platelets at a number of levels, decreasing aggregation, causing disaggregation, preventing adhesion and the release phenomenon. More recently it has also been found to have a protective effect on white cell activation. It would therefore seem to possess most of the properties required to prevent or block the abnormalities occurring in the ischaemic microcirculation. This may indeed be one of its normal roles.
There is little evidence that decreased production of prostacyclin plays a primary role in ischaemia, but administered in pharmacological doses it may well have a protective beneficial effect. Prostacyclin was first used clinically in 1979 when six patients with CLI were reported to have obtained considerable benefit from its infusion. Prostacy-c1in has a short half-life, is denatured in the lung and it has to be infused intra-arterially for therapeutic purposes. This, together with its instability, has made it less than ideal as a routine treatment. Analogues of prostacyclin were then developed which were stable, not inactivated in the lung and could therefore be administered intravenously. More interestingly, orally active prostacyclin analogues have now become available for clinical investigation.
Clinical trials of prostacyclin and its analogues
When trying to reach a conclusion about the clinical efficacy of drugs in the management of patients with CLI, only prospective randomized placebo-controlled trials, where treatment was continued for more than a few days, should be considered. In the past 12 years the results of trials involving approximately 2000 patients with CLI have been published from Europe. The largest number of patients (740) were entered into trials using the prostacyclin analogue iloprost, in six placebo-controlled prospective randomized trials. The patient populations were similar in all these trials. Patients had ischaemic rest pain, gangrene or ulcers and were deemed unsuitable for any further vascular intervention. Over a quarter of the patient group had previous attempts at vascular reconstruction, often more than once. Thus they represented the worst end of the spectrum of CLI. The treatment regimen was also identical in all these trials; the dose was gradually increased up to 2 nglkg/h over 6 h per day until the patient had significant side-effects, and it was then decreased one step. In effect, the dose was individually titrated. The treatment duration, however, varied in different trials from 2 to 4 weeks. Only in the three later trials was there a formal follow-up of 4-6 months after the end of treatment and in two of these the follow-up rate was 99%. On an intention to treat analysis of major amputation or death at the end of follow-up the rate differences in favour of iloprost in these three trials were 19.1% in the UK trial, 17% in the French trial and 14% in the Swedish trial. The UK trial had the largest number of patients and the rate difference was statistically significant (2p=O.0 19). In the two trials where 99% of the data was available at follow-up, 53 patients died or had a major amputation out of 132 receiving iloprost compared to 73 out of 128 patients receiving standard therapy only. These results were supported by the much 'softer' end-points of evidence of ulcer healing or pain relief at the end of the treatment period,"
In one study, iloprost was compared to PGE. (prostaglandin E 1 ) using the same study design, and essentially no difference was found between these two prostanoids in terms of efficacy. There is no fundamental reason to believe that one formulation is going to be very significantly more efficacious than another, although they may differ in terms of ease of administration and possibly sideeffects. PGE. has also been extensively investigated in patients with severe leg ischaemia. Results suggest efficacy in terms of ulcer healing and relief of rest pain, but few studies have looked at amputation or death during follow-up." New formulations, such as Lipo PGE., allowing very brief periods of infusion, have been extensively used in Japan and are being evaluated in Europe.
Trials and tribulations of studies of prostanoids and CLI
A number of problems have become apparent in the clinical testing of prostanoids: Prostanoid drug therapy for PAOD 157 randomize patients who had just developed CLI into pharmacological versus surgical treatment. Therefore in all the studies reported patients were only entered when surgical treatment had failed and amputation seemed inevitable. Almost certainly a high proportion of these end-stage patients were beyond any type of successful treatment, as the ischaemic changes in the tissues must have been irreversible. Patients with undetectable Doppler pressures at the ankle were not excluded in any trial.
3) A trial of a prostanoid cannot be completely doubleblind, particularly if administration involves titrating the dosage up to the level where side-effects are produced. Although side-effects were inevitably also reported in the placebo group, their incidence was far higher in the patients treated with prostacyclins. This abence of complete double-blindness is probably only worrying when the end-points of the studies are relatively soft. This was the case in some of the earlier trials where efficacy was assessed at the end of the treatment period in terms of 'responder rates'. It then became apparent that the appropriate end-point for any treatment study in patients with CLI is probably major amputation or death during a follow-up period of at least 6 months. It is, of course, most unlikely that any significant bias could have entered into the assessment of these hard end-points. 4) Maximum follow-up in these trials was 6 months. Any difference in major amputation or mortality between the treatment and placebo groups could well have been abolished if patients had been followed for longer, say a year. This information will also clearly be necessary to evaluate the true costlbenefit ratio of such treatment.
Other uses of prostanoids in CLI
It is probably quite wrong to view any pharmacological treatment in CLI as necessarily an alternative to surgical revascularization. The parmacological properties of prostanoids could be equally useful in trying to improve the results of reopening procedures either by surgery or by catheter techniques. With both these reopening modalities the biggest problem is the high reocclusion rate in the first 6-12 months. This can be as high as 70-80% in these patients.
Early results using a single bolus of a prostacyclin analogue at the end of a distal bypass operation showed a very significant improvement in the graft blood flow for at least a week and appeared to show a clinical benefit in terms of patency at I year," However, a subsequent larger multicentre randomized study did not confirm the improved patency. Retrospective analysis of the results suggests that this may well have been because treatment was only given for 3 days after surgery; there is no reason why it could not have been given for longer. There have been no controlled randomized studies of a prostanoid used as an adjuvant to angioplasty or other catheter procedures in patients with CLI.
There will always be some patients with CLI who will inevitably come to a major amputation, and the risk of poor healing of amputation stumps is still as much of a problem as it has ever been. In most published series, approximately 15-20% of below-knee amputations did not heal and had to be revised, usually after a considerable delay, to an above-knee level. It is widely believed that the blood flow necessary to achieve healing is l(}'-15 times greater than the blood flow necessary to keep skin alive once it has healed. It therefore seems an attractive proposition to test prostacyclin analogues as an adjunct at the time of major amputation to aid healing. The only large published trial, in 713 below-knee amputees from 51 centres, showed no significant benefit in the treatment group. Rather intriguingly, in one centre, where four times more patients were recruited than in any other centre, the adjuvant use of a prostacyclin analogue decreased the re-amputation rate following below-knee amputations from 21% to 8%.9
Use of prostaglandins in claudicants
So far there have only been a few smaller studies in this indication. This is doubtless because of the high incidence of side-effects and the equally high cost, which would make this form of pharmacotherapy unacceptable in a relatively benign long-term condition. Nevertheless it is an area which is now being looked at again in light of our knowledge that a relatively short period of treatment (in CLI) appears to provide a much longer-term benefit and the absence of any real evidence that high doses, which are on the verge of producing side-effects, are really necessary to achieve such a benefit. The treatment of claudicants has also become a more real possibility with the advent of prostacyclin analogues which can be used in nonhospitalized patients.
One of the most dramatic results in claudicants has been published recently, where PGE, was compared to pentoxfylline or placebo. All the patients received extensive exercise training; altogether, 44 severe claudicants were entered and treated for only 4 weeks. Nevertheless, the pentoxfylline and the placebo group only increased the claudication distance by a little over 100%, by comparison to a remarkable improvement of 600% in patients receiving PGE,.'o The future of prostanoid drug therapy in PAOD I) The principal problem for patients with any form of PAOD will remain earlier cardiovascular mortality and increased morbidity. The present bench-mark for prophylaxis in this area has to be antiplatelet drugs, such as aspirin, but it is quite conceivable that either intermittent or continuous treatment with an orally active prostanoid alone or in combination with aspirin Vascular Medicine 1996; 1: 155-158 may provide greater protection. This would have to be at a dose virtually completely free of side-effects. 2) As far as the leg itself is concerned, the principal present problem is the high failure rate of distal arterial reconstructions. On the basis of present results it is quite conceivable that adjuvant intravenous prostanoid during the postoperative period in hospital followed by longer-term maintenance therapy with an oral prostanoid could significantly improve the results of distal surgical bypasses. 3) Increasingly there are reports of patients with CLI treated solely by a catheter reopening technique. Distal angioplasties are becoming more successful technically, but have a high early reocclusion rate. Again adjuvant intravenous prostanoid followed by oral maintenance treatment may be effective. 4) Finally, improved selection of patients, possibly on the basis of microcirculatory as well as rnacrocirculatory investigations, may identify a group of patients with early CLI who would benefit from primary treatment with a prostanoid, either intravenously or orally. The days when prostanoid therapy is only tried in patients as a last resort, before amputation, are probably past. The acceptance of prostanoid therapy, or indeed any medical therapy, as an alternative to high risk revascularization will probably have to go hand in hand with an increased acceptance of vascular medicine as an equal partner with vascular surgery.
